Long-Acting Injectable HIV Treatment Still Appears Safe and Effective—and Largely Accessible Despite COVID-19 Disruptions
Research newly presented at the IDWeek 2020 conference yields further promising data on injectable cabotegravir/rilpivirine, as well as encouraging info regarding COVID-19 disruptions in treatment delivery.
Taken together, these studies appear to confirm that weight gain is a class effect of INSTIs, albeit with potential differences between individual drugs—and much left to be learned about the health impact.
Although the mechanism and long-term implications remain unclear, these studies affirm that the effect is occurring—and that a person’s prior HIV treatment regimen may play a role.
B/F/TAF Holds Up as Switch Regimen for Black People Living With HIV, Including Those With Resistance
While the most striking aspect of the study was its demographic focus, the baseline resistance profile of the participants was also key.
The findings add to a growing body of research showing that it’s other co-morbidities, not HIV, that lead to worse health outcomes from COVID-19—at least among individuals who are on stable antiretroviral therapy.
The international news story that broke at AIDS 2020, explained by the lead researcher.
COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
These studies presented at AIDS 2020 explore the benefits and challenges.
Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
A CROI 2020 roundup of studies on birth control and women living with HIV.